Search

Your search keyword '"Giaccone, Giuseppe"' showing total 1,868 results
Start Over Author "Giaccone, Giuseppe"
1,868 results on '"Giaccone, Giuseppe"'

1. The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposals for the N and the M Components for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors

Author

Fang, Wentao, Girard, Nicolas, Cilento, Vanessa, Goren, Emily, Dibaba, Daniel, Ruffini, Enrico, Ahmad, Usman, Appel, Sarit, Bille, Andrea, Boubia, Souheil, Brambilla, Cecilia, Cangir, Ayten Kayi, Detterbeck, Frank, Falkson, Conrad, Filosso, Pier Luigi, Giaccone, Giuseppe, Guerrera, Francesco, Huang, James, Infante, Maurizio, Kim, Dong Kwan, Lucchi, Marco, Marino, Mirella, Marom, Edith M., Nicholson, Andrew G., Okumura, Meinoshin, Rami-Porta, Ramon, Rimner, Andreas, Simone, Charles B., II, and Asamura, Hisao

Published
2024
Full Text
View/download PDF

2. The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: A Re-Assessment of the International Thymic Malignancy Interest Group/International Association for the Study of Lung Cancer Lymph Node Map for Thymic Epithelial Tumors for the Forthcoming Ninth Edition of the TNM Classification of Malignant Tumors

Author

Marom, Edith M., Fang, Wentao, Ruffini, Enrico, Detterbeck, Frank, Ahmad, Usman, Appel, Sarit, Bille, Andrea, Boubia, Souheil, Brambilla, Cecilia, Cilento, Vanessa, Cangir, Ayten Kayi, Falkson, Conrad, Filosso, Pier Luigi, Giaccone, Giuseppe, Girard, Nicolas, Goren, Emily, Guerrera, Francesco, Huang, James, Infante, Maurizio, Kim, Dong-Kwan, Lucchi, Marco, Marino, Mirella, Nicholson, Andrew G., Okumura, Meinoshin, Rami-Porta, Ramon, Rimner, Andreas, Simone, Charles B., II, and Asamura, Hisao

Published
2023
Full Text
View/download PDF

3. The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposal for a Stage Classification for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors

Author

Ruffini, Enrico, Huang, James, Cilento, Vanessa, Goren, Emily, Detterbeck, Frank, Ahmad, Usman, Appel, Sarit, Bille, Andrea, Boubia, Souheil, Brambilla, Cecilia, Cangir, Ayten Kayi, Falkson, Conrad, Fang, Wentao, Filosso, Pier Luigi, Giaccone, Giuseppe, Girard, Nicolas, Guerrera, Francesco, Infante, Maurizio, Kim, Dong Kwan, Lucchi, Marco, Marino, Mirella, Marom, Edith M., Nicholson, Andrew G., Okumura, Meinoshin, Rami-Porta, Ramon, Rimner, Andreas, Simone, Charles B., II, and Asamura, Hisao

Published
2023
Full Text
View/download PDF

4. The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Proposal for the T Component for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors

Author

Okumura, Meinoshin, Marino, Mirella, Cilento, Vanessa, Goren, Emily, Ruffini, Enrico, Dibaba, Daniel, Ahmad, Usman, Appel, Sarit, Bille, Andrea, Boubia, Souheil, Brambilla, Cecilia, Cangir, Ayten Kayi, Detterbeck, Frank, Falkson, Conrad, Fang, Wentao, Filosso, Pier Luigi, Giaccone, Giuseppe, Girard, Nicolas, Guerrera, Francesco, Huang, James, Infante, Maurizio, Kim, Dong Kwan, Lucchi, Marco, Marom, Edith M., Nicholson, Andrew G., Rami-Porta, Ramon, Rimner, Andreas, Simone, Charles B., II, and Asamura, Hisao

Published
2023
Full Text
View/download PDF

5. The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: An Overview of the Central Database Informing Revision of the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors

Author

Rimner, Andreas, Ruffini, Enrico, Cilento, Vanessa, Goren, Emily, Ahmad, Usman, Appel, Sarit, Bille, Andrea, Boubia, Souheil, Brambilla, Cecilia, Cangir, Ayten Kayi, Detterbeck, Frank, Falkson, Conrad, Fang, Wentao, Filosso, Pier Luigi, Giaccone, Giuseppe, Girard, Nicolas, Guerrera, Francesco, Huang, James, Infante, Maurizio, Kim, Dong Kwan, Lucchi, Marco, Marino, Mirella, Marom, Edith M., Nicholson, Andrew G., Okumura, Meinoshin, Rami-Porta, Ramon, Simone, Charles B., II, and Asamura, Hisao

Published
2023
Full Text
View/download PDF

8. A Knock-In Mouse Model of Thymoma With the GTF2I L424H Mutation

Author

He, Yongfeng, Kim, In-Kyu, Bian, Jing, Polyzos, Alexander, Di Giammartino, Dafne Campigli, Zhang, Yu-Wen, Luo, Ji, Hernandez, Maria O., Kedei, Noemi, Cam, Maggie, Borczuk, Alain C., Lee, Trevor, Han, Yumin, Conner, Elizabeth A., Wong, Madeline, Tillo, Desiree C., Umemura, Shigeki, Chen, Vincent, Ruan, Lydia, White, Jessica B., Miranda, Ileana C., Awasthi, Parirokh P., Altorki, Nasser K., Divakar, Prajan, Elemento, Olivier, Apostolou, Effie, and Giaccone, Giuseppe

Published
2022
Full Text
View/download PDF

9. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial

Author

Conforti, Fabio, Zucali, Paolo Andrea, Pala, Laura, Catania, Chiara, Bagnardi, Vincenzo, Sala, Isabella, Della Vigna, Paolo, Perrino, Matteo, Zagami, Paola, Corti, Chiara, Stucchi, Sara, Barberis, Massimo, Guerini-Rocco, Elena, Di Venosa, Benedetta, De Vincenzo, Fabio, Cordua, Nadia, Santoro, Armando, Giaccone, Giuseppe, and De Pas, Tommaso Martino

Published
2022
Full Text
View/download PDF

12. Pulmonary cancers across different histotypes share hybrid tuft cell/ionocyte-like molecular features and potentially druggable vulnerabilities

Author

Yamada, Yosuke, Belharazem-Vitacolonnna, Djeda, Bohnenberger, Hanibal, Weiß, Christel, Matsui, Naoko, Kriegsmann, Mark, Kriegsmann, Katharina, Sinn, Peter, Simon-Keller, Katja, Hamilton, Gerhard, Graeter, Thomas, Preissler, Gerhard, Ott, German, Schölch, Sebastian, Nakajima, Naoki, Yoshizawa, Akihiko, Haga, Hironori, Date, Hiroshi, Thomas, Roman K., Petrini, Iacopo, Giaccone, Giuseppe, Ströbel, Philipp, and Marx, Alexander

Published
2022
Full Text
View/download PDF

14. Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC.

Author

Goldberg, Michael E, Montesion, Meagan, Young, Lauren, Suh, James, Greenbowe, Joel, Kennedy, Mark, Giaccone, Giuseppe, Akerley, Wallace L, Dowlati, Afshin, Creelan, Benjamin C, Hicks, James K, Hesketh, Paul J, Kelly, Karen L, Riess, Jonathan W, Miller, Vincent A, Stephens, Philip J, Frampton, Garrett M, Ali, Siraj, Gregg, Jeffrey P, and Albacker, Lee A

Subjects
Humans, Carcinoma, Non-Small-Cell Lung, Antineoplastic Agents, Protein Kinase Inhibitors, Cohort Studies, Drug Resistance, Neoplasm, Mutation, Adult, Aged, Aged, 80 and over, Middle Aged, Female, Male, ErbB Receptors, Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, and over, General Science & Technology
Abstract

After sequential treatment with first- and third-generation EGFR tyrosine kinase inhibitors (TKIs), EGFR-mutant non-small cell lung cancers frequently harbor multiple resistance mutations in exon 20 of EGFR including T790M, mediating resistance to first-generation TKIs, and at codons 792, 796, or 797 mediating resistance to third-generation TKIs. However, whether these resistance mutations are in cis or trans has therapeutic implications for patients. We analyzed a cohort of 29 patients with NSCLC harboring EGFR mutations at codons 792, 796, or 797 to establish the configuration of these mutations. We performed hybrid capture-based, next-generation sequencing on formalin-fixed paraffin-embedded biopsy tissue or liquid biopsy. 27 samples had both a T790M mutation and a mutation at codons 792, 796, or 797. In all of these cases, the mutations were found in the cis configuration; the trans configuration was not observed. Two patients' samples harbored a mutation at codon 797 but no T790M mutation. In these two cases, longitudinal analysis showed earlier biopsies harbored EGFR T790M, which was undetectable following osimertinib treatment. Treatment of one these patients with both first- and third-generation EGFR TKIs resulted in a mixed response. Here we describe multiple configurations of EGFR T790M and third-generation TKI resistance mutations at codons 792, 796, and 797. These mutations are most commonly found in cis, which confers resistance to all current EGFR TKIs. We also describe two patients that exhibited T790M loss with acquisition of a mutation at codon 797. In addition, one of these patients, with an EGFR C797S in a lung biopsy was subsequently found to have EGFR C797N in a later biopsy of pleural fluid, highlighting the dynamic multiclonal nature of advanced NSCLC.

Published
2018

15. Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Author

Jassem, Jacek, de Marinis, Filippo, Giaccone, Giuseppe, Vergnenegre, Alain, Barrios, Carlos H., Morise, Masahiro, Felip, Enriqueta, Oprean, Cristina, Kim, Young-Chul, Andric, Zoran, Mocci, Simonetta, Enquist, Ida, Komatsubara, Kimberly, McCleland, Mark, Kuriki, Hiroshi, Villalobos, Monette, Phan, See, Spigel, David R., and Herbst, Roy S.

Published
2021
Full Text
View/download PDF

17. The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non–Small Cell Lung Cancer

Author

Asamura, Hisao, Rusch, Valerie, Rami-Porta, Ramón, Araujo, Luiz Henrique, Beer, David, Bertoglio, Pietro, Beyruti, Ricardo, Bille, Andrea, Bolejack, Vanessa, Boubia, Souheil, Brambilla, Elisabeth, Brierley, James D., Cangir, A.K., Carbone, David, Chansky, Kari, Crowley, John, Darling, Gail, Detterbeck, Frank, D’Journo, Xavier Benoit, Donnington, Jessica, Eberhardt, Wilfried, Edwards, John, Erasmus, Jeremy, Falkson, Conrad, Fang, Wentao, Fennell, Dean, Fong, Kwun, Galateau-Salle, Françoise, Gautschi, Oliver, Gill, Ritu, Giroux, Dorothy, Giuliani, Meredith, Goo, Jin Mo, Hasegawa, Seiki, Hirsch, Fred, Hoffman, Hans, Hofstetter, Wayne, Huang, James, Joubert, Philippe, Kernstine, Kemp, Kerr, Keith, Kim, Young Tae, Kim, Hong Kwan, Kindler, Hedy, Lievens, Yolande, Liu, Hui, Low, Donald E., Lyons, Gustavo, MacMahon, Heber, Marino, Mirella, Marom, Edith, Matilla, José-María, van Meerbeeck, Jan, Montuenga, Luis M., Nicholson, Andrew, Nishimura, Katie, Nowak, Anna, Opitz, Isabelle, Okumura, Meinoshin, Osarogiagbon, Raymond U., Pass, Harvey, de Perrot, Marc, Prosch, Helmut, Rice, David, Rimner, Andreas, Ruffini, Enrico, Sakai, Shuji, Van Schil, Paul, Singh, Navneet, Stoll-D’Astice, Amy, Su´rez, Francisco, Terra, Ricardo M., Travis, William D., Tsao, Ming S., Ugalde, Paula, Waller, David, Watanabe, Shun-ichi, Wiens, Jacinta, Wistuba, Ignacio, Yatabe, Yasushi, Jiang, Liyan, Kubota, Kaoru, Turna, Akif, Weksler, Benny, Tzukazan, Maria Teresa, Tammemägi, Martin, Powell, Charles, Naidich, David, Liu, Hongxu, Armato, Samuel, Brunelli, Alex, Cardillo, Giuseppe, David, Elizabeth, Fournier, Brigitte, Krasnik, Mark, Kubota, Kauro, Labbe, Catherine, Lim, Eric, Putora, Paul Martin, Rocco, Gaetano, Filosso, Pier Luigi, Kondo, Kazuya, Kim, Dong Kwan, Giaccone, Giuseppe, Lucchi, Marco, Infante, Maurizio, Rice, Thomas, Ferguson, Mark, Adsusmilli, Prasad, Travis, William, Suárez, Francisco, Kubota, Kaura, Shun-ichi, Watanabe, Hisao Asamura, Nicholson, Andrew G., Ramón, Rami-Porta, Edith Marom, Tsao, Ming, Shun-ichi, Watanabe, Ming Tsao, Guiliani, Meredith, Brierley, James, Terra, Ricardo, Osarogiagbon, Ray, Montuenga, Luis, Wang, Hongwei, Nakajima, Jun, Galateau, Françoise, Ostrowski, Marcin, Goo, Jim Mo, Travis, Bill, Matilla, Jose Maria, St. Pierre, Carolle, Tzukazan, Ma Teresa, Girard, Nicholas, Rimmer, Andreas, Galateau, Francoise, Adusumilli, Prasad, D’Journo, Xavier, Low, Donald, Rosenthal, Adam, Edwards, John G., Donington, Jessica, Galateau-Sallé, Françoise, Hoffmann, Hans, Marom, Edith M., Tsao, Ming-Sound, Giroux, Dorothy J., Shemanski, Lynn, and Krasnik, Marc

Published
2020
Full Text
View/download PDF

18. The International Association for the Study of Lung Cancer Thymic Tumors Staging Project: The Impact of the Eighth Edition of the Union for International Cancer Control and American Joint Committee on Cancer TNM Stage Classification of Thymic Tumors

Author

Ruffini, Enrico, Fang, Wentao, Guerrera, Francesco, Huang, James, Okumura, Meinoshin, Kim, Dong Kwan, Girard, Nicolas, Billè, Andrea, Boubia, Souheil, Cangir, Ayten Kayi, Detterbeck, Frank, Falkson, Conrad, Filosso, Pier Luigi, Giaccone, Giuseppe, Kondo, Kazuya, Infante, Maurizio, Lucchi, Marco, Marino, Mirella, Marom, Edith M., Nicholson, Andrew G., Rimner, Andreas, Rami-Porta, Ramon, and Asamura, Hisao

Published
2020
Full Text
View/download PDF

20. 606 IMpower110: Tertiary lymphoid structures (TLS) and clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with first-line atezolizumab or chemotherapy

Author

Srivastava, Minu K, primary, Gayevskiy, Velimir, additional, Ma, Vy, additional, Estay, Ivette, additional, Rodas, Miguel Lopez de, additional, Rajendran, Barani Kumar, additional, Hoang, Tien, additional, Ballinger, Marcus, additional, Amin, Reena, additional, Herbst, Roy S, additional, Marinis, Filippo de, additional, Giaccone, Giuseppe, additional, Jassem, Jacek, additional, Spigel, David R, additional, Schalper, Kurt, additional, Koeppen, Hartmut, additional, Shames, David S, additional, Johnston, Robert, additional, Giltnane, Jennifer M, additional, and Nabet, Barzin Y, additional

Published
2023
Full Text
View/download PDF

26. Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis.

Author

Sala, Isabella, Pagan, Eleonora, Pala, Laura, Oriecuia, Chiara, Musca, Marco, Specchia, Claudia, De Pas, Tommaso, Cortes, Javier, Giaccone, Giuseppe, Postow, Michael, Gelber, Richard D., Bagnardi, Vincenzo, and Conforti, Fabio

Subjects
IMMUNE checkpoint inhibitors, CLINICAL trials, OVERALL survival, SURVIVAL rate, TREATMENT effectiveness, IPILIMUMAB
Abstract

Introduction: There is debate on which are the best surrogate endpoint and metric to capture treatment effect on overall survival (OS) in RCTs testing immune-checkpoint inhibitors (ICIs). Methods: We systematically searched for RCTs testing ICIs in patients with advanced solid tumors. Inclusion criteria were: RCTs i) assessing PD-(L)1 and CTLA-4 inhibitors either as monotherapy or in combination with another ICI, and/or targeted therapy, and/or chemotherapy, in patients with advanced solid tumors; ii) randomizing at least 100 patients. We performed a meta-analysis of RCTs to compare the surrogacy value of PFS and modified-PFS (mPFS) for OS in RCTs testing ICIs, when the treatment effect is measured by the hazard ratio (HR) for OS, and by the HR and the ratio of restricted mean survival time (rRMST) for PFS and mPFS. Results: 61 RCTs (67 treatment comparisons and 36,034 patients) were included in the analysis. In comparisons testing ICI plus chemotherapy, HRPFS and HRmPFS both had a strong surrogacy value (R2 = 0.74 and R2 = 0.81, respectively). In comparisons testing ICI as monotherapy, HRPFS was the best surrogate, although having a moderate correlation (R2 = 0.58). In comparisons testing ICI plus other treatment(s), the associations were very weak for all the surrogate endpoints and treatment effect measures, with R2 ranging from 0.01 to 0.22. Conclusion: In RCTs testing ICIs, the value of potential surrogates for HROS was strongly affected by the type of treatment(s) tested. The evidence available supports HRPFS as the best surrogate, and disproves the use of alternative endpoints, such as the mPFS, or treatment effect measures, such as the RMST. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. The IASLC Thymic Epithelial Tumors Staging Project: Proposals for the N and the M Components for the Forthcoming (9th) Edition of the TNM Classification of Malignant Tumors

Author

Fang, Wentao, primary, Girard, Nicolas, additional, Cilento, Vanessa, additional, Goren, Emily, additional, Dibaba, Daniel, additional, Ruffini, Enrico, additional, Ahmad, Usman, additional, Appel, Sarit, additional, Bille, Andrea, additional, Boubia, Souheil, additional, Brambilla, Cecilia, additional, Cangir, Ayten Kayi, additional, Detterbeck, Frank, additional, Falkson, Conrad, additional, Filosso, Pier Luigi, additional, Giaccone, Giuseppe, additional, Guerrera, Francesco, additional, Huang, James, additional, Infante, Maurizio, additional, Kim, Dong Kwan, additional, Lucchi, Marco, additional, Marino, Mirella, additional, Marom, Edith M., additional, Nicholson, Andrew G., additional, Okumura, Meinoshin, additional, Rami-Porta, Ramon, additional, Rimner, Andreas, additional, Simone, Charles B., additional, and Asamura, Hisao, additional

Published
2023
Full Text
View/download PDF

33. 30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)

Author

de Marinis, Filippo, Ciardiello, Fortunato, Baas, Paul, Crinò, Lucio, Giaccone, Giuseppe, Grossi, Francesco, Hellmann, Matthew D., Mok, Tony S.K., Lena, Hervè, Paz-Ares, Luis, Rodriguez-Abreu, Delvys, Von Pavel, Joachim, and Gridelli, Cesare

Published
2018
Full Text
View/download PDF

37. 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Author

Azzoli, Christopher G, Temin, Sarah, Aliff, Timothy, Baker, Sherman, Brahmer, Julie, Johnson, David H, Laskin, Janessa L, Masters, Gregory, Milton, Daniel, Nordquist, Luke, Pao, William, Pfister, David G, Piantadosi, Steven, Schiller, Joan H, Smith, Reily, Smith, Thomas J, Strawn, John R, Trent, David, and Giaccone, Giuseppe

Subjects
Clinical Trials and Supportive Activities, Cancer, Lung Cancer, Lung, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Carcinoma, Non-Small-Cell Lung, Clinical Trials, Phase III as Topic, Humans, Lung Neoplasms, Neoplasm Staging, Randomized Controlled Trials as Topic, American Society of Clinical Oncology, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeAn American Society of Clinical Oncology (ASCO) focused update updates a single recommendation (or subset of recommendations) in advance of a regularly scheduled guideline update. This document updates one recommendation of the ASCO Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer (NSCLC) regarding switch maintenance chemotherapy.Clinical contextRecent results from phase III clinical trials have demonstrated that in patients with stage IV NSCLC who have received four cycles of first-line chemotherapy and whose disease has not progressed, an immediate switch to alternative, single-agent chemotherapy can extend progression-free survival and, in some cases, overall survival. Because of limitations in the data, delayed treatment with a second-line agent after disease progression is also acceptable.Recent dataSeven randomized controlled trials of carboxyaminoimidazole, docetaxel, erlotinib, gefitinib, gemcitabine, and pemetrexed have evaluated outcomes in patients who received an immediate, non-cross resistant alternative therapy (switch maintenance) after first-line therapy.RecommendationIn patients with stage IV NSCLC, first-line cytotoxic chemotherapy should be stopped at disease progression or after four cycles in patients whose disease is stable but not responding to treatment. Two-drug cytotoxic combinations should be administered for no more than six cycles. For those with stable disease or response after four cycles, immediate treatment with an alternative, single-agent chemotherapy such as pemetrexed in patients with nonsquamous histology, docetaxel in unselected patients, or erlotinib in unselected patients may be considered. Limitations of this data are such that a break from cytotoxic chemotherapy after a fixed course is also acceptable, with initiation of second-line chemotherapy at disease progression.

Published
2011

38. [American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer].

Author

Azzoli, Christopher G, Baker, Sherman, Temin, Sarah, Pao, William, Aliff, Timothy, Brahmer, Julie, Johnson, David H, Laskin, Janessa L, Masters, Gregory, Milton, Daniel, Nordquist, Luke, Pfister, David G, Piantadosi, Steven, Schiller, Joan H, Smith, Reily, Smith, Thomas J, Strawn, John R, Trent, David, and Giaccone, Giuseppe

Subjects
Humans, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents, Neoplasm Staging, Antineoplastic Protocols, Societies, Medical, United States, Guidelines as Topic, Oncology & Carcinogenesis
Published
2010

39. American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage Ⅳ Non–Small-Cell Lung Cancer

Author

AZZOLI, Christopher G, Baker, Sherman, TEMIN, Sarah, William, PAO, ALIFF, Timothy, BRHMER, Julie, JOHNSON, David H, LASKIN, Janessa L, MASTERS, Gregory, MILTON, Daniel, NORDQUIST, Luke, PFISTER, David G, PIANTADOSI, Steven, SCHILLER, Joan H, SMITH, Reily, SMITH, Tomas J, STRWN, John R, TRENT, David, GIACCONE, Giuseppe, 丁, 燕, 南, 娟, and 刘, 谦

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Lung Cancer, Cancer, Lung, Antineoplastic Agents, Antineoplastic Protocols, Carcinoma, Non-Small-Cell Lung, Guidelines as Topic, Humans, Lung Neoplasms, Neoplasm Staging, Societies, Medical, United States, Oncology & Carcinogenesis
Published
2010

40. American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Author

Azzoli, Christopher G, Baker, Sherman, Temin, Sarah, Pao, William, Aliff, Timothy, Brahmer, Julie, Johnson, David H, Laskin, Janessa L, Masters, Gregory, Milton, Daniel, Nordquist, Luke, Pfister, David G, Piantadosi, Steven, Schiller, Joan H, Smith, Reily, Smith, Thomas J, Strawn, John R, Trent, David, and Giaccone, Giuseppe

Subjects
Lung, Clinical Trials and Supportive Activities, Cancer, Rare Diseases, Clinical Research, Orphan Drug, Lung Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Neoplasm Staging, American Society of Clinical Oncology, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

The purpose of this article is to provide updated recommendations for the treatment of patients with stage IV non-small-cell lung cancer. A literature search identified relevant randomized trials published since 2002. The scope of the guideline was narrowed to chemotherapy and biologic therapy. An Update Committee reviewed the literature and made updated recommendations. One hundred sixty-two publications met the inclusion criteria. Recommendations were based on treatment strategies that improve overall survival. Treatments that improve only progression-free survival prompted scrutiny of toxicity and quality of life. For first-line therapy in patients with performance status of 0 or 1, a platinum-based two-drug combination of cytotoxic drugs is recommended. Nonplatinum cytotoxic doublets are acceptable for patients with contraindications to platinum therapy. For patients with performance status of 2, a single cytotoxic drug is sufficient. Stop first-line cytotoxic chemotherapy at disease progression or after four cycles in patients who are not responding to treatment. Stop two-drug cytotoxic chemotherapy at six cycles even in patients who are responding to therapy. The first-line use of gefitinib may be recommended for patients with known epidermal growth factor receptor (EGFR) mutation; for negative or unknown EGFR mutation status, cytotoxic chemotherapy is preferred. Bevacizumab is recommended with carboplatin-paclitaxel, except for patients with certain clinical characteristics. Cetuximab is recommended with cisplatin-vinorelbine for patients with EGFR-positive tumors by immunohistochemistry. Docetaxel, erlotinib, gefitinib, or pemetrexed is recommended as second-line therapy. Erlotinib is recommended as third-line therapy for patients who have not received prior erlotinib or gefitinib. Data are insufficient to recommend the routine third-line use of cytotoxic drugs. Data are insufficient to recommend routine use of molecular markers to select chemotherapy.

Published
2009

41. Prognostic factors of overall survival (OS) in non-small cell lung cancer (NSCLC) patients after failure on immune checkpoint inhibitors (IO) treated with anticancer vaccine OSE2101 or chemotherapy (CT) in phase 3 ATALANTE-1 randomized trial.

Author

Besse, Benjamin, primary, Felip, Enriqueta, additional, Campelo, Rosario Garcia, additional, Cobo, Manuel, additional, Mascaux, Celine, additional, Madroszyk, Anne, additional, Cappuzzo, Federico, additional, Hilgers, Werner, additional, Romano, Giampiero, additional, Denis, Fabrice, additional, Viteri Ramirez, Santiago, additional, Debieuvre, Didier, additional, Razaq, Mohammad, additional, Schuette, Wolfgang, additional, Zer, Alona, additional, Attali, Pierre, additional, Montestruc, François, additional, Vasseur, Berangere, additional, Dziadziuszko, Rafal, additional, and Giaccone, Giuseppe, additional

Published
2023
Full Text
View/download PDF

44. The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer

Author

Goldstraw, Peter, Rami-Porta, Ramón, Asamura, Hisao, Ball, David, Beer, David G., Beyruti, Ricardo, Bolejack, Vanessa, Chansky, Kari, Crowley, John, Detterbeck, Frank, Erich Eberhardt, Wilfried Ernst, Edwards, John, Galateau-Sallé, Françoise, Giroux, Dorothy, Gleeson, Fergus, Groome, Patti, Huang, James, Kennedy, Catherine, Kim, Jhingook, Kim, Young Tae, Kingsbury, Laura, Kondo, Haruhiko, Krasnik, Mark, Kubota, Kaoru, Lerut, Antoon, Lyons, Gustavo, Marino, Mirella, Marom, Edith M., van Meerbeeck, Jan, Mitchell, Alan, Nakano, Takashi, Nicholson, Andrew G., Nowak, Anna, Peake, Michael, Rice, Thomas, Rosenzweig, Kenneth, Ruffini, Enrico, Rusch, Valerie, Saijo, Nagahiro, Van Schil, Paul, Sculier, Jean-Paul, Shemanski, Lynn, Stratton, Kelly, Suzuki, Kenji, Tachimori, Yuji, Thomas, Charles F., Jr., Travis, William, Tsao, Ming S., Turrisi, Andrew, Vansteenkiste, Johan, Watanabe, Hirokazu, Wu, Yi-Long, Baas, Paul, Erasmus, Jeremy, Hasegawa, Seiki, Inai, Kouki, Kernstine, Kemp, Kindler, Hedy, Krug, Lee, Nackaerts, Kristiaan, Pass, Harvey, Rice, David, Falkson, Conrad, Filosso, Pier Luigi, Giaccone, Giuseppe, Kondo, Kazuya, Lucchi, Marco, Okumura, Meinoshin, Blackstone, Eugene, Cavaco, F. Abad, Barrera, E. Ansótegui, Arca, J. Abal, Lamelas, I. Parente, Obrer, A. Arnau, Jorge, R. Guijarro, Ball, D., Bascom, G.K., Orozco, A. I. Blanco, Castro, M. A. González, Blum, M.G., Chimondeguy, D., Cvijanovic, V., Defranchi, S., de Olaiz Navarro, B., Campuzano, I. Escobar, Vidueira, I. Macía, Araujo, E. Fernández, García, F. Andreo, Fong, K.M., Corral, G. Francisco, González, S. Cerezo, Gilart, J. Freixinet, Arangüena, L. García, Barajas, S. García, Girard, P., Goksel, T., Budiño, M. T. González, Casaurrán, G. González, Blanco, J. A. Gullón, Hernández, J. Hernández, Rodríguez, H. Hernández, Collantes, J. Herrero, Heras, M. Iglesias, Elena, J. M. Izquierdo, Jakobsen, E., Kostas, S., Atance, P. León, Ares, A. Núñez, Liao, M., Losanovscky, M., Lyons, G., Magaroles, R., De Esteban Júlvez, L., Gorospe, M. Mariñán, McCaughan, B., Kennedy, C., Íñiguez, R. Melchor, Sorribes, L. Miravet, Gozalo, S. Naranjo, Álvarez de Arriba, C., Delgado, M. Núñez, Alarcón, J. Padilla, Cuesta, J. C. Peñalver, Park, J.S., Pass, H., Fernández, M. J. Pavón, Rosenberg, M., Ruffini, E., Rusch, V., Sánchez de Cos Escuín, J., Vinuesa, A. Saura, Mitjans, M. Serra, Strand, T.E., Subotic, D., Swisher, S., Terra, R., Thomas, C., Tournoy, K., Van Schil, P., Velasquez, M., Wu, Y.L., Yokoi, K., Detterbeck, Frank C., Rusch, Valerie W., Vallières, Eric, and Crowley, John J.

Published
2017
Full Text
View/download PDF

46. The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer

Author

Fernandez, Harvey R., Gadre, Shreyas M., Tan, Mingjun, Graham, Garrett T., Mosaoa, Rami, Ongkeko, Martin S., Kim, Kyu Ah, Riggins, Rebecca B., Parasido, Erika, Petrini, Iacopo, Pacini, Simone, Cheema, Amrita, Varghese, Rency, Ressom, Habtom W, Zhang, Yuwen, Albanese, Christopher, Üren, Aykut, Paige, Mikell, Giaccone, Giuseppe, and Avantaggiati, Maria Laura

Published
2018
Full Text
View/download PDF

50. Supplementary Data from An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non–Small-Cell Lung Cancer

Author

Roepman, Paul, primary, Jassem, Jacek, primary, Smit, Egbert F., primary, Muley, Thomas, primary, Niklinski, Jacek, primary, van de Velde, Tony, primary, Witteveen, Anke T., primary, Rzyman, Witold, primary, Floore, Arno, primary, Burgers, Sjaak, primary, Giaccone, Giuseppe, primary, Meister, Michael, primary, Dienemann, Hendrik, primary, Skrzypski, Marcin, primary, Kozlowski, Miroslaw, primary, Mooi, Wolter J., primary, and van Zandwijk, Nico, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results